English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

The US FDA Granted Orphan Drug Designation to Yisheng Biopharma's Biological Product for Hepatocellular Carcinoma

Dec. 1, 2016

The U.S. Food and Drug Administration has granted orphan drug designation for the lead product candidate, YS-ON-001, of Beijing-based Yisheng Biopharma, a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines. The drug for the treatment of hepatocellular carcinoma is a promising biological product with immunomodulating effects, such as the induction of anti-tumor cytokines, the activation of NK cells, the regulation of macrophage polarization, and the suppression of regulatory T cells.